Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benestent II: back to the future.

H Emanuelsson1, W J van der Giessen, P W Serruys

  • 1Division of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden.

Journal of Interventional Cardiology
|November 4, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data of the Insect Biome Atlas: a metabarcoding survey of the terrestrial arthropods of Sweden and Madagascar.

Scientific data·2025
Same author

Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.

Cardiovascular intervention and therapeutics·2014
Same author

Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.

International journal of clinical practice·2009
Same author

The immediate and long-term effect of optimal balloon angioplasty on the absolute coronary blood flow velocity reserve. A subanalysis of the DEBATE study. Doppler Endpoints Balloon Angioplasty Trial Europe.

European heart journal·2001
Same author

Coagulation and complement activation.

Biomaterials·2001
Same author

Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators.

European heart journal·2000

Heparin-coated coronary stents show promise in preventing blood clots after implantation. The Benestent II trial aims to minimize post-procedure anticoagulation, reducing risks associated with heparin treatment.

Area of Science:

  • Cardiovascular medicine
  • Biomaterials science
  • Interventional cardiology

Background:

  • Heparin coating is known to reduce thrombotic complications on blood-contacting surfaces.
  • Previous studies in animal models suggest heparin-coated coronary stents can prevent subacute thrombotic occlusion.

Purpose of the Study:

  • To evaluate the clinical feasibility of heparin-coated coronary stents.
  • To minimize or eliminate the need for deep anticoagulation post-stent implantation.
  • To assess the impact on revascularization procedures and late morphological changes.

Main Methods:

  • The Benestent II pilot trial is designed as a stepwise study.
  • Focus on exploring the feasibility of delaying deep anticoagulation.
  • Quantitative coronary angiography will be used for late morphological assessment.

Related Experiment Videos

Main Results:

  • The study is designed to test the feasibility and efficacy of heparin-coated stents.
  • Primary endpoint is minimizing or excluding post-implantation heparin treatment.
  • Secondary endpoints include revascularization rates and late stent morphology.

Conclusions:

  • Heparin-coated coronary stents offer a potential strategy to reduce thrombotic events.
  • The Benestent II trial will provide crucial data on the clinical utility of this approach.
  • Reducing anticoagulation requirements post-procedure is a key objective.